中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.015 seconds)

    Liquid vaccines for multiple meningococcal serogroups
    2.
    发明授权
    Liquid vaccines for multiple meningococcal serogroups 有权
    液体疫苗用于多种脑膜炎球菌血清群

    公开(公告)号：US09180204B2

    公开(公告)日：2015-11-10

    申请号：US14319331

    申请日：2014-06-30

    Applicant: Novartis AG

    Inventor： Mario Contorni

    IPC: A61K39/00 ,  A61K39/02 ,  A61K39/095 ,  A61K39/116 ,  A61K47/48 ,  A61K39/102 ,  A61K9/19 ,  A61K39/39

    CPC classification number: A61K47/4833 ,  A61K9/19 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

    Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilization. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.

    Abstract translation: 来自脑膜炎球菌血清群C，W135和Y的共轭荚膜糖在单剂量组合时在人体中是安全的和免疫原性的。 当加入来自血清群A的共轭荚膜糖时，保留这种效果。 这些缀合的抗原可以以单一水剂量稳定地组合，而不需要冻干。 通过使用少量定义的多肽抗原可以实现对血清群B感染的广泛保护。 这些多肽抗原可以与糖抗原组合，而不会损害五种血清群中的任何一种的保护功效。 即使添加Hib缀合物也能保留效力。 通过加入源自血清群B菌株的蛋白质抗原来增强血清群W135缀合物的功效。 向脑膜炎球菌共轭物中添加Hib缀合物增强了针对脑膜炎球菌血清群W135的总体活性。

    Adjuvanting meningococcal factor H binding protein
    3.
    发明授权
    Adjuvanting meningococcal factor H binding protein 有权
    补充脑膜炎球菌因子H结合蛋白

    公开(公告)号：US08834888B2

    公开(公告)日：2014-09-16

    申请号：US13767853

    申请日：2013-02-14

    Applicant: Novartis AG

    Inventor： Mario Contorni ,  Lorenzo Tarli

    IPC: A61K39/00 ,  A61K39/02 ,  A61K39/095 ,  A61K39/385

    CPC classification number: A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

    Abstract translation: 已经提出因子H结合蛋白（fHBP）用于免疫血清群B脑膜炎球菌（'MenB'）。 （i）确保在等于或低于佐剂点零点（PZC）的pH下进行吸附，和/或（ii）选择fHBP和佐剂，可以有效地将该抗原吸附到羟基磷酸铝佐剂上 等电点/ PZC在5.0至7范围内，和/或（iii）选择具有等电点高于佐剂PZC的fHBP，并使用缓冲液使pH达到PZC的1.2pH单位内。 该吸附对于包含多种fHBP变体的组合物以及在应避免使用氢氧化铝佐剂的情况下特别有用。 缓冲的药物组合物可以包括至少两种不同的脑膜炎球菌fHBP抗原，两者都至少85％被羟基磷酸羟丙酯佐剂吸附。

    Adjuvanting meningococcal factor H binding protein
    4.
    发明授权
    Adjuvanting meningococcal factor H binding protein 有权
    补充脑膜炎球菌因子H结合蛋白

    公开(公告)号：US09572884B2

    公开(公告)日：2017-02-21

    申请号：US14307001

    申请日：2014-06-17

    Applicant: Novartis AG

    Inventor： Mario Contorni ,  Lorenzo Tarli

    IPC: A61K39/00 ,  A61K47/02 ,  A61K39/095

    CPC classification number: A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

    Abstract translation: 已经提出因子H结合蛋白（fHBP）用于免疫血清群B脑膜炎球菌（'MenB'）。 （i）确保在等于或低于佐剂点零点（PZC）的pH下进行吸附，和/或（ii）选择fHBP和佐剂，可以有效地将该抗原吸附到羟基磷酸铝佐剂上 等电点/ PZC在5.0至7范围内，和/或（iii）选择具有等电点高于佐剂PZC的fHBP，并使用缓冲液使pH达到PZC的1.2pH单位内。 该吸附对于包含多种fHBP变体的组合物以及在应避免使用氢氧化铝佐剂的情况下特别有用。 缓冲的药物组合物可以包括至少两种不同的脑膜炎球菌fHBP抗原，两者都至少85％被羟基磷酸羟丙酯佐剂吸附。

    STABLE COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
    5.
    发明申请
    STABLE COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS 审中-公开
    稳定的组合物，用于免疫印刷油菜

    公开(公告)号：US20150044251A1

    公开(公告)日：2015-02-12

    申请号：US14366362

    申请日：2012-12-21

    Applicant: NOVARTIS AG

    Inventor： Mario Contorni ,  Lorenzo Tarli ,  Anna Coslovi ,  Michele Sotgiu

    IPC: A61K39/085

    CPC classification number: A61K39/085

    Abstract: Adding stabilizing additives to immunogenic compositions is effective in enhancing antigen stability. Suitable stabilizing additives include EDTA (ethylenediaminetetraacetic acid), sucrose, arginine, protease inhibitors, glycerol and/or citrate.

    Abstract translation: 向免疫原性组合物中加入稳定添加剂对提高抗原稳定性是有效的。 合适的稳定添加剂包括EDTA（乙二胺四乙酸），蔗糖，精氨酸，蛋白酶抑制剂，甘油和/或柠檬酸盐。

Patent Agency Ranking